4.5 Article

Power analysis for idiographic (within-subject) clinical trials: Implications for treatments of rare conditions and precision medicine

Journal

BEHAVIOR RESEARCH METHODS
Volume -, Issue -, Pages -

Publisher

SPRINGER
DOI: 10.3758/s13428-022-02012-1

Keywords

Within-subject clinical trials; Idiographic; Statistical power; Effect size; Hierarchical modeling; Piecewise regression; Monte Carlo simulation; Rare diseases; Precision medicine

Funding

  1. National Institutes of Health, National Center for Advancing Translational Sci-ences [R21 TR002402]

Ask authors/readers for more resources

This study examines the impact of various factors on the statistical power to detect treatment outcomes in idiographic clinical trials. The factors that are under researchers' control, such as sample size and number of observations per participant, as well as factors that are largely outside of researchers' control, such as population size and treatment effect size, are tested. The study finds that larger treatment effect sizes have the greatest impact on power, followed by more observations per participant and larger samples.
Power analysis informs a priori planning of behavioral and medical research, including for randomized clinical trials that are nomothetic (i.e., studies designed to infer results to the general population based on interindividual variabilities). Far fewer investigations and resources are available for power analysis of clinical trials that follow an idiographic approach, which emphasizes intraindividual variabilities between baseline (control) phase versus one or more treatment phases. We tested the impact on statistical power to detect treatment outcomes of four idiographic trial design factors that are under researchers' control, assuming a multiple baseline design: sample size, number of observations per participant, proportion of observations in the baseline phase, and competing statistical models (i.e., hierarchical modeling versus piecewise regression). We also tested the impact of four factors that are largely outside of researchers' control: population size, proportion of intraindividual variability due to residual error, treatment effect size, and form of outcomes during the treatment phase (phase jump versus gradual change). Monte Carlo simulations using all combinations of the factors were sampled with replacement from finite populations of 200, 1750, and 3500 participants. Analyses characterized the unique relative impact of each factor individually and all two-factor combinations, holding all others constant. Each factor impacted power, with the greatest impact being from larger treatment effect sizes, followed respectively by more observations per participant, larger samples, less residual variance, and the unexpected improvement in power associated with assigning closer to 50% of observations to the baseline phase. This study's techniques and R package better enable a priori rigorous design of idiographic clinical trials for rare diseases, precision medicine, and other small-sample studies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available